Novel Prognostic Biomarkers in Metastatic and Locally Advanced Colorectal Cancer: Micronuclei Frequency and Telomerase Activity in Peripheral Blood Lymphocytes
| Autor: | Nikolaos Razos, Aristidis Tsatsakis, John Tsiaoussis, Polychronis Stivaktakis, Aikaterini Berdiaki, Taxiarchis Konstantinos Nikolouzakis, Elena Vakonaki, Athanasios Alegakis, John Souglakos |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Telomerase Treatment response Colorectal cancer Locally advanced Disease 03 medical and health sciences 0302 clinical medicine locally advanced rectal cancer Internal medicine medicine RC254-282 Original Research business.industry metastatic colorectal cancer micronuclei frequency biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens telomerase activity medicine.disease Peripheral blood 030104 developmental biology 030220 oncology & carcinogenesis Micronucleus test prognosis business Progressive disease |
| Zdroj: | Frontiers in Oncology, Vol 11 (2021) Frontiers in Oncology |
| DOI: | 10.3389/fonc.2021.683605/full |
| Popis: | PurposeDue to the current practice on colorectal cancer (CRC) management, chemoresistance is most often recognized at the end of the treatment. Therefore, effective and easy-to-use prognostic biomarkers are needed.Experimental DesignWe evaluated the prognostic significance of two novel CRC biomarkers: a) micronuclei frequency (MNf) in 55 metastatic CRC (mCRC) and 21 locally advanced rectal cancer (laRC) patients using cytokinesis block micronucleus assay (CBMN assay) and b) telomerase activity (TA) in 23 mCRC and five laRC patients using TRAP-ELISA. Both biomarkers were evaluated in peripheral blood lymphocytes (PBLs) before, at the middle, and at the end of the therapy (approximately 0, 3, and 6 months) for mCRC patients before, at the end of the therapy, and after surgery for laRC patients.ResultsOverall, MNf demonstrated significant prognostic value since a decrease of MNf less than 29% between middle and initial MNf measurements can discriminate between progressive and stable/responsive disease with sensitivity of 36% and specificity of 87.0% while being able to identify responsive disease with sensitivity of 72.7% and specificity of 59.3%. On the other hand, TA presented a significant trend of increase (p = 0.07) in patients with progressive disease at the middle measurement.ConclusionsThe findings of this study suggest that the MN frequency may serve as a promising prognostic biomarker for the monitoring of the treatment response of patients with CRC, while TA should be evaluated in a larger group of patients to further validate its significance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|